Skip to content

Clinical trial on the efficacy and safety of the combination of "Bev Tine Soothing and Cleansing essence (No. 2)" and "Bev Tine Brightening Coagulation Cream (No. 2)" in the auxiliary treatment of facial grade II acne

Clinical trial on the efficacy and safety of the combination of "Bev Tine Soothing and Cleansing essence (No. 2)" and "Bev Tine Brightening Coagulation Cream (No. 2)" in the auxiliary treatment of facial grade II acne

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082751
Enrollment
Unknown
Registered
2024-04-07
Start date
2024-04-08
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-acne

Interventions

Test group:Using a combination of two test products to assist in drug therapy
Control group:Using medication for treatment

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) 18-45 years old, regardless of gender; 2) Facial skin lesions, clinically diagnosed as Grade II acne patients (mainly manifested as acne and papules, with no more than 20 inflammatory skin lesions in the entire area); 3) The patient voluntarily participates in clinical observation and signs an informed consent form. They are willing to cooperate with follow-up observation and have good communication and understanding skills.

Exclusion criteria

Exclusion criteria: 1) Acne patients with pustules, cysts, or nodules on the face; 2) Use topical medications (such as retinoic acid) for treatment within two weeks; 3) Systemic treatment (oral antibiotics or retinoids) or physical and chemical therapy within one month; 4) There are other skin diseases in the affected area that may significantly affect the efficacy evaluation 5) Diseases related to female patients treated with estrogen or estrogen like hormones; 6) Individuals who suffer from severe allergic diseases or have had cosmetic allergies in the past 1-2 years; 7) Individuals with severe heart, brain, lung, liver, kidney function, and hematopoietic system disorders; 8) Pregnant women, breastfeeding or recently planned pregnancies (limited to females only); 9) Individuals with a history of psychological and mental illness, recent history of alcoholism or drug abuse; 10) Any other circumstances that the researcher deems unsuitable for participation in the trial.

Design outcomes

Primary

MeasureTime frame
Facial acne skin lesion count;

Secondary

MeasureTime frame
GAIS score;Porphyrin;Redness;Moisture content of stratum corneum;TEWL;Sebum;Security assessment;Acne-Specific Quality of Life Questionnaire;

Countries

China

Contacts

Public ContactLi Li

West China Hospital, Sichuan University

hxskincosm@qq.com+86 28 8542 2075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026